Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Natasha Frank
Brigham and Women's Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Ticeba GmbH
Intellectual property rights (e.g., royalties, patents, copyrights) not from the awardee Institution
The research seeks to validate the regenerative potential of ABCB5+ from limbal stem cells and skin for limbal stem cell deficiency, and to create an LSC Biobank for clinical transplantation and conduct studies. Dr. Frank’s spouse is a consultant to the company, which is active in stem cell research and regenerative medicine, and has a license related to limbal ABCB5+ stem cells. If the research develops a treatment for LSCD, then there would be increased interest in obtaining LSC for use in the treatment, which could affect the financial interests of the company.
Multipotent ABCB5-positive cell therapeutics for corneal disease
PROJECT NARRATIVE Patients with a corneal disease called a 'limbal stem cell deficiency' lose their vision and ultimately become blind because they develop an opaque cornea that is unable to transmit light to the retina. We discovered a new gene called 'ABCB5' that is expressed on limbal stem cells that can be used to purify these cells for transplantation to affected patients. The goal of this project is to translate our laboratory research findings to develop new clinically relevant ABCB5 stem cell-based therapies to treat these patients.
Filed on April 17, 2018.
Tell us what you know about Natasha Frank's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Natasha Frank filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Natasha Frank | Brigham and Women's Hospital | Conflict of Interest | Ticeba GmbH | $60,000 - $79,999 |
| Natasha Frank | Boston Children's Hospital | Conflict of Interest | Triceba Gmbh and Rheacell Gmbh & Co. KG | $0 - $4,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.